Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?

High-dose therapy followed by autologous hematopoietic stem cell (HSC) transplant is considered standard of care for eligible patients with multiple myeloma. The optimal collection strategy should be effective in procuring sufficient HSC while maintaining a low toxicity profile. Currently available...

Descripción completa

Detalles Bibliográficos
Autores principales: Wallis, Whitney D, Qazilbash, Muzaffar H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661122/
https://www.ncbi.nlm.nih.gov/pubmed/29104859
http://dx.doi.org/10.5500/wjt.v7.i5.250
_version_ 1783274423120297984
author Wallis, Whitney D
Qazilbash, Muzaffar H
author_facet Wallis, Whitney D
Qazilbash, Muzaffar H
author_sort Wallis, Whitney D
collection PubMed
description High-dose therapy followed by autologous hematopoietic stem cell (HSC) transplant is considered standard of care for eligible patients with multiple myeloma. The optimal collection strategy should be effective in procuring sufficient HSC while maintaining a low toxicity profile. Currently available mobilization strategies include growth factors alone, growth factors in combination with chemotherapy, or growth factors in combination with chemokine receptor antagonists; however, the optimal strategy has yet to be elucidated. Herein, we review the risks and benefits of each approach.
format Online
Article
Text
id pubmed-5661122
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-56611222017-11-03 Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy? Wallis, Whitney D Qazilbash, Muzaffar H World J Transplant Review High-dose therapy followed by autologous hematopoietic stem cell (HSC) transplant is considered standard of care for eligible patients with multiple myeloma. The optimal collection strategy should be effective in procuring sufficient HSC while maintaining a low toxicity profile. Currently available mobilization strategies include growth factors alone, growth factors in combination with chemotherapy, or growth factors in combination with chemokine receptor antagonists; however, the optimal strategy has yet to be elucidated. Herein, we review the risks and benefits of each approach. Baishideng Publishing Group Inc 2017-10-24 2017-10-24 /pmc/articles/PMC5661122/ /pubmed/29104859 http://dx.doi.org/10.5500/wjt.v7.i5.250 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Review
Wallis, Whitney D
Qazilbash, Muzaffar H
Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
title Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
title_full Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
title_fullStr Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
title_full_unstemmed Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
title_short Peripheral blood stem cell mobilization in multiple myeloma: Growth factors or chemotherapy?
title_sort peripheral blood stem cell mobilization in multiple myeloma: growth factors or chemotherapy?
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5661122/
https://www.ncbi.nlm.nih.gov/pubmed/29104859
http://dx.doi.org/10.5500/wjt.v7.i5.250
work_keys_str_mv AT walliswhitneyd peripheralbloodstemcellmobilizationinmultiplemyelomagrowthfactorsorchemotherapy
AT qazilbashmuzaffarh peripheralbloodstemcellmobilizationinmultiplemyelomagrowthfactorsorchemotherapy

Ejemplares similares